Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Runfei Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Sichuan Hairong Pharmaceutical, a subsidiary of the Yangtze River Pharmaceutical Group. The product is designed based on the TCM principle of "tonifying the kidney and moistening the lung," which is intended to address syndromes characterized by deficiencies in both the lung and kidney systems. It is primarily indicated for the treatment of chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis, particularly during their stable phases. The oral solution aims to alleviate symptoms such as persistent cough, shortness of breath, and fatigue, while potentially improving lung function and reducing the frequency of acute exacerbations. As a complex herbal mixture, it utilizes the synergistic effects of multiple botanical extracts to harmonize bodily functions and strengthen the respiratory system's resilience.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen Runfei Oral Liquid.